342 results about "Anticoagulation Agents" patented technology

Compounds of formula (I) are useful as inhibitors of trypsin like serine protease enzymes such as thrombin, factor VIIa, factor Xa, TF/FVIIa, and trypsin. These compounds could be useful to treat and/or prevent clotting disorders, and as anticoagulating agents.

This invention provides methods for the localized delivery of supplemented tissue sealants, wherein the supplemented tissue sealants comprise at least one composition which is selected from one or more antibodies, analgesics, anticoagulants, anti-inflammatory compounds, antimicrobial compositions, antiproliferatives, cytokines, cytotoxins, drugs, growth factors, interferons, hormones, lipids, demineralized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like. Further provided are methods of using the site-specific supplemented tissue sealants, including preparation of a biomaterial.

A pharmaceutical composition comprising at least one of components (a) and at least one of components (b) shown in below: (a) a compound represented by the general formula (I) (wherein R1 represents a hydrogen atom or a hydroxyl group) or an acid addition salt or hydrate thereof; and (b) an ameliorant of cerebral circulation, a vasodilator, a cerebral protecting drug, an brain metabolic stimulants, an anticoagulant, an antiplatelet drug, a thrombolytic drug, an amelirant of psychiatric symptom, a antihypertensive drug, an antianginal drug, a diuretic, a cardiotonic, an antiarrhythmic drug, an antihyperlipidemic drug, an immunosuppressant, or a pharmaceutically acceptable salt (except the components shown in (a)). It is useful as a preventive or remedy for cerebrovascular disorders and cardiac diseases.

There is provided compounds of formula I,wherein R1, Rx, Y, Ry, n and B have meanings given in the description which are useful as competitive inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

The present invention provides novel phenylglycinamide derivatives of Formula (I) or (IV):

or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables W, W₁, Y, Z, R⁷, R⁸, R⁹, and R¹¹ are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.

The invention relates to an extraction method of platelet rich plasma (PRP) and extracted PRP and particularly relates to a method for extracting PRP from blood. The method comprises the following steps of: (a) putting the collected whole blood in a container containing an anticoagulant, and fully and uniformly mixing the blood and the anticoagulant; (b) putting the blood mixed with the anticoagulant in a centrifuge tube, carrying out primary centrifugation, and enabling the blood to be divided into three layers; (c) extracting the uppermost layer and most of the middle layer, transferring the uppermost layer and most of the middle layer into a new centrifuge tube, mixing uniformly and carrying out secondary centrifugation; and (d) discarding the plasma at the upper layer of the centrifuge tube, and resuspending the precipitated plasma by utilizing the remaining plasma, thus obtaining the PRP. The method provided by the invention has the advantages that the operation process is simple, the yield is high and the concentration of platelet in rich plasma is high.

The invention discloses a blood sample collecting device. The collecting device comprises a collecting tube, wherein an orifice of the collecting tube is provided with a sealing rubber plug, the outside of the rubber plug is provided with a protective cap, the collecting tube is filled with additives, the additives are composed of a blood anticoagulation, a hemocyte nucleic acid stabilizing agent, a blood plasma nucleic acid stabilizing agent, and a pH buffer solution; the blood anticoagulation is one or more of oxalate, heparinate and citrate, the pH buffer solution is one of glycine-sodium hydroxide-hydrochloric acid buffer solution; the hemocyte nucleic acid stabilizing agent is one or more of allantoin, 5,5-dimethyl hydantoin and oxazolidine; the blood plasma nucleic acid stabilizing agent is N-acetic acid azomethine, N-(3-acetic acid-amylamine)azomethine. The blood sample collecting device simultaneously contains the hemocyte nucleic acid stabilizing agent and the blood plasma nucleic acid stabilizing agent, and does not contain free aldehyde material, so that the blood sample can be stored in long term at normal temperature, and the free nucleic acid level of the blood sample can be stabilized, and the completeness of the free nucleic acid can be maintained.

A method of performing regional citrate anticoagulant dialysis of a patient's blood includes flowing blood from and back to the patient through an extracorporeal circuit including a dialyzer having semi-permeable dialysis membranes and a dialysate chamber surrounding the membranes. The method further includes flowing a dialysate containing calcium and citrate through the dialysate chamber of the dialyzer and introducing citrate into the patient's blood upstream of the dialyzer, whereby the patient's blood is dialyzed. The method can further include predicting the concentration of systemic ionized calcium in the blood of the patient at any point in the dialysis treatment or post-dialysis, such as by a mathematical model. The method can further include statistically correcting the preliminary predicted post-dialysis concentration of systemic ionized calcium in the patient's blood to provide a final predicted post-dialysis systemic ionized calcium concentration. The method can further include statistically correcting the preliminary predicted systemic ionized calcium concentration for any time point during the dialysis treatment to provide a final predicted systemic ionized calcium concentration for that time point.

The present invention provides compounds and methods for antagonizing the anticoagulant effect of an anticoagulant agent that is selected from UFH, LMWH, and a heparin/LMWH derivative in a patient comprising administering to the patient a compound of the invention or a salt thereof, or a composition comprising the same.

A meat modifying agent includes an oil-in-water emulsion containing (A) 10 to 60 parts by weight of an animal fat/oil, (B) 0.01 to 1 part by weight of a starch, (C) 15 to 40 parts by weight of a saccharified starch, (D) 0.3 to 8.0 parts by weight of a non-ionic surfactant, (E) 0.41 to 7.5 parts by weight of a viscosity-increasing polysaccharide, (F) 0.02 to 0.05 parts by weight of an anti-oxidant, (G) 0.03 to 0.1 parts by weight of a metal sequestering agent, (H) 0.005 to 0.5 parts by weight of a pH adjusting agent, (I) a preservative containing 0.00001 to 0.005 parts by weight of thujaplicin, and (J) water.

The invention belongs to the blood product technology field, and discloses a preparation method for leukocyte-depleted platelet rich plasma. The method comprises the following steps: firstly, anticoagulants and blood are drawn and mixed, and whole blood to be separated is obtained; secondly, first centrifugation is carried out, a centrifugate divided into three layers from bottom to top is obtained, and platelet and plasma components in the upper layer are obtained; thirdly, the obtained upper layer components are centrifuged again, and platelet deposition at the bottom and a plasma supernatant are formed; part of the plasma supernatant is drawn, the platelet deposition is subjected to resuspension by the left plasma supernatant, and leukocyte-depleted platelet rich plasma is prepared. The method achieves elimination of leukocytes and enrichment of platelets at the same time, operation is convenient, consumed time is short, the technical indexes of the prepared plasma product are better than technical indexes of present products with the same kind. Centrifugation for two times in the method can be carried out in two centrifuge tubes respectively, or be carried out in one centrifugal device. The invention provides a centrifugal device used for performing the preparation method.

The subject invention concerns methods and materials for determining the presence or absence of bacterial or fungal infection in a blood sample. In one embodiment, a method of the invention comprises exposing an anticoagulant treated blood sample to freezing the sample to a solid, followed by thawing of the sample and then agitation of the sample to develop foam and then observing the rate that foam dissolves.

A quality control material and a calibrator for calibrating blood cell analyzers comprise simian whole blood plasma, anticoagulant, preservation solution, cell mimics and stabilizer, wherein the weight ratio of the simian whole blood plasma to the anticoagulant is 10:1, the weight ratio of the mixture of the simian whole blood plasma and the anticoagulant to the preservation solution is 10:1, 1 percent by weight of stabilizer is added into the mixture of the three components, and the cell mimics are added according to the amount and concentration of products. The prices of the quality control material and the calibrator are reasonable, the quality of the quality control material and the calibrator is reliable, and the quality control material and the calibrator meet national sanitary requirement, and also can more accurately test the precision and stability of a blood cell analyzer.

The invention provides an artificial blood vessel and a preparation method thereof which help solve a technical problem that degradation speed of a conventional artificial blood vessel is not matchedwith growth and proliferation speed of inoculated cells. The artificial blood vessel consists of a vascular stent and the inoculated cells; the vascular stent consists of a inner layer stent, an intermediate layer stent and an outer layer stent that are all connected tightly in order; the inner layer stent is a porous fiber circular tube-shaped structure formed by polyethylene succinate and an anticoagulant; the intermediate layer stent is a porous fiber circular tube-shaped structure formed by hydrogel-based material, bioceramic material, and growth factors; the inoculated cells are adhered to pores of the intermediate layer stent which are filled by the inoculated cells; the outer layer stent is a porous fiber circular tube-shaped structure formed by the polybutylene succinate; the invention also discloses a preparation method of the artificial blood vessel which can be widely applied to the field of implantable medical devices.

The present invention provides an anticoagulant agent including a first element capable of inhibiting coagulation and a second element capable of targeting an activated platelet wherein upon administration of element directs the first element to the activated platelet. Also provided is a probe for detecting a blood vessel abnormality including (a) a binding element capable of targeting an activated platelet and (b) a label. Applicant has shown that agents and probes directed to activated platelets are useful in the diagnosis and therapy of coagulation disorders.

Amidino derivatives represented by the following general formula (I):

{where X is a group represented by R¹SO₂NR²— (wherein R¹ represents optionally substituted C_6-14 aryl, etc. and R² represents hydrogen atom, etc.), etc., Ar¹ represents 2,6-naphthylene, etc., R³ represents hydrogen atom, etc. and Y represents carboxyphenyl, etc.}

and their pharmacologically acceptable salts or solvates.

The invention belongs to the technical field of preparation of platelet rich plasma, and in particular discloses a method for preparing PRP (Platelet Rich Plasma) through a manual two-step centrifugation method. The method comprises the following steps: centrifuging 25 ml of whole blood mixed with an anticoagulant for 6 minutes at centrifugal force of 800 g for the first time by adopting the two-step centrifugation method, absorbing plasma on the upper layer and on boundary layer in the layered whole blood, and arranging the plasma in an another centrifugal tube; centrifuging for the second time, namely centrifuging for 5 minutes at centrifugal force of 1400 g, and absorbing about 4 ml of the layered plasma on the middle layer to obtain the platelet rich plasma. According to the PRP prepared by the technology, the platelet concentration is 886.33*10<9>/L, the mean corpuscular hemoglobin in the PRP is 27.72 g/L, and the clinical treatment requirements are met.